- Company
- Ilaris’s reimb again at a standstill… bumpy road ahead
- by Eo, Yun-Ho Mar 12, 2024 05:48am
- The road to reimbursement for ‘Ilaris,’ a treatment used by around ten patients in Korea, continues to be bumpy ahead. According to Dailypharm’s coverage, the government’s ‘reimbursement adequacy’ decision made for Novartis Korea’s Ilaris (canakinumab) has been put on hold after the company failed to meet the government's request f
- Company
- SK Bioscience breaks ground on vaccine plant expansion
- by Chon, Seung-Hyun Mar 11, 2024 05:55am
- SK Bioscience announced on the 7th that the company broke ground on a vaccine plant, ‘Andong L HOUSE,’ located in Andong, Gyeongsangbuk-do, South Korea. The plant will be expanded to install new equipment. This expansion aims to increase vaccine production capacity for global supply by raising the existing vaccine plant within L House
- Company
- Jemperli can be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Mar 11, 2024 05:55am
- Jemperli, the first immuno-oncology option introduced to the field of endometrial cancer, can now be prescribed in general hospitals in Korea. According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed the drug committee (DC) reviews of tertiary hospitals in Korea. Including the Seoul National University
- Company
- Hemlibra shows big sales rise, Advate loses ground
- by Kim, Jin-Gu Mar 11, 2024 05:55am
- The market for Type A hemophilia has shifted significantly, with JW Pharmaceutical's 'Hemlibra' expanding sales considerably after receiving reimbursement expansion. However, Takeda Pharmaceutical’s 'Advate,' which has been recording the highest sales in the market for an extended period, lost ground. Advate sales decreased by over 20%
- Company
- AZ’s EGPA drug Fasenra receives orphan drug designation
- by Eo, Yun-Ho Mar 11, 2024 05:55am
- AstraZeneca's antibody drug Fasenra has been designated as an orphan drug in Korea for its eosinophilic granulomatosis indication. The Ministry of Food and Drug Safety announced so through an official orphan drug designation notice on the 7th. More specifically, the drug received an orphan drug designation as a treatment for eosinophilic
- Policy
- 1st KOR trial of 'STX-721' to treat EGFR mutant NSCLC begins
- by Lee, Hye-Kyung Mar 11, 2024 05:55am
- The US pharmaceutical company Scorpion Therapeutics has started conducting the first clinical trial of its new EGFR-targeted therapy, 'STX-721,' on patients in South Korea. The Ministry of Food and Drug Safety (MFDS) has approved ‘The first human clinical trial of STX-721 enrolling patients with locally advanced or metastatic non-small cell
- Policy
- Fasenra's reimb application passes DREC review
- by Lee, Tak-Sun Mar 11, 2024 05:55am
- Fasenra, the last of 3 antibody drugs used for severe asthma to apply for reimbursement in Korea, has now passed the Drug Reimbursement Evaluation Committee (DREC) stage, increasing the likelihood of its reimbursement. The drug, like Nucala, is seeking reimbursement through the risk-sharing arrangement (RSA) scheme. The industry is paying att
- Policy
- Pfizer starts trial for its RSV drug sisunatovir on adults
- by Lee, Hye-Kyung Mar 8, 2024 05:19am
- Pfizer will initiate a clinical trial for its respiratory syncytial virus (RSV) infection drug sisunatovir in adults in Korea. The company had previously initiated a trial for the drug on pediatric patients in Korea. On the 7th, the Ministry of Food and Drug Safety (MFDS) approved Pfizer's "interventional Phase II/III, adaptive, multicent
- Policy
- Pharmas impacted by ‘minoxidil’ bioequivalence test result
- by Lee, Hye-Kyung Mar 8, 2024 05:18am
- Bioequivalence test outcomes result in different paths for prescription drugs containing the active ingredient ‘minoxidil,’ which was first introduced as a hypertension drug but is now commonly used as a hair-loss drug. The Ministry of Food and Drug Safety (MFDS) recently issued a two-month sales suspension order on Binex’s ‘Bimo Tab
- Policy
- CSL Behring’s hemophilia B Tx Idelvion reattempts reimb
- by Lee, Tak-Sun Mar 8, 2024 05:18am
- CSL Behring, a subsidiary of Australian multinational pharmaceutical giant CSL, is reattempting to receive reimbursement benefits for its hemophilia treatment in Korea. CSL Behring holds the domestic marketing authorization and reimbursement rights for the hemophilia drug Afstyla Inj which was developed by SK Chemicals. According to in
